| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -21.8 | -22.1 |
| EPS (diluted, $ a share) | $-0.15 | $-0.41 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ALXO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Alx Oncology Holdings Inc: key numbers
- Share price
- $1.00Close, Nov 17
- Market cap
- $130M
- Shares outstanding
- 129.27MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Alx Oncology Holdings Inc
All →Alx Oncology Holdings Financial Results
ALX Oncology reported third quarter 2026 financial results, ending the period with $147.2 million in cash and investments, which is expected to fund operations through the first half of 2028. The company highlighted clinical progress for evorpacept and ALX2004, with topline data from the ASPEN-09-Breast trial now expected in the second half of 2027.
“Throughout the third quarter, we continued to make significant progress across both the ASPEN-09-Breast and ALX2004 clinical trials. The recent publication of ASPEN-06 results in Nature Medicine further reinforces the promise of evorpacept and our biomarker-driven development strategy.”
Jason Lettmann, Chief Executive Officer of ALX Oncology
Alx Oncology Holdings Other 8-K Filing
ALX Oncology entered into exchange agreements with certain stockholders, including funds affiliated with Blackstone, RA Capital, and venBio, to exchange 13,353,384 shares of common stock for an equivalent number of pre-funded warrants. This transaction is a non-cash exchange of equity classes intended to manage beneficial ownership levels, as the warrants include exercise limitations to prevent holders from exceeding specific ownership thresholds.
- Counterparty
- Blackstone Annex Master Fund L.P.